Cardioprotection of Shenfu preparata on cardiac myocytes through cytochrome P450 2J3

Cardioprotective HaemodialysisFX CorDiaxDesigned to Dialyse. Built for CardioprotectionS P TThe reduction of risk factors for cardiovascular diseases (CVD) is core to the development of dialysis systems and products at Fresenius Medical Care. Outstanding cardioprotection must be reflected in all levels of product development and application.There have been tremendous improvements in the quality and efficacy of haemodialysis (HD) therapyin recent years. Despite this, cardiovascular diseases (CVD) remain the leading cause of death for patients with end-stage renal disease (ESRD).Cardioprotective Haemodialysis Wide-ranging cardioprotection Protect your PatientServicesOver 30 years of experience in dialysis at your service.Project Planning and ConsultingTraining and EducationTechnical ServicesWater Quality Service (WQS)Medical Information Services ProductsState-of-the-art technologies enable advancedcardioprotective therapies.C orDiax product line:• 5008 CorDiax and 5008S CorDiax• FX CorDiax haemo dia filter• BCM-Body Composition MonitorC lassix product line:• 4008S classix• FX classix dialysersTherapy Data Management System (TDMS)Online Purification Cascade (OPC) Cardioprotective23Moreover, both overall and cardiovascular mortality are markedly greater in ESRD patients than in the general population. This is why we put Cardioprotective Haemo-dialysis on the SPOT. A comprehensive approach that includes services, products and therapies is needed toTherapiesCardioprotective therapies designed by the world market leader in haemodialysis.High-Flux dialysisHighVolume HDF®Advanced Fluid ManagementOutcomesAchieving better outcomes with cardioprotective therapies.Reduced mortality riskFewer cardiovascular complications Optimised use of resourcesachieve the best therapeutic performance – meaning improved clinical outcomes and better quality of life, enhanced control of therapy costs, and simpler, safer handling.HaemodialysisP R ODUCTS45SPOT on:CVD are the largestcauses of death in dialysis patients.High-Flux membranesenhance middlemolecule removal and reduce risk factors.F X CorDiax forenhanced survival and better outcomes.reducing the induction of inflammatory cascades that are central to many aspects of CVD.State-of-the-art technologies such as Fresenius’ Nano Controlled Spinning (NCS™) and INLINE steam sterilisation are the result of continual innovation at Fresenius Medical Care.Advances in material and production technologies have permitted improvements in the wall structure by opening up the support region of the membrane.The Helixone ®plus membrane in the new FX CorDiax dialysers improves the clearance of middle molecules while the loss of essential blood components such as albumin is curtailed. The Helixone ®plus membrane upgrades the FX-class ® dialyser into the CorDiax product line, which provides products for superior cardioprotective therapies.61The authors concluded that “… treating patients with online haemodiafiltration and FX CorDiax 60 instead of FX 60 dialysers results in significantly increased reduction ratios of middle sized molecules without clinically relevant changes in albumin loss.1 Maduell et.al.; ERA-EDTA Congress 2013, May 20, Poster Number MP 390.Removal ratios of FX 60 and FX CorDiax 60 dialysers in post-dilution HDF 1(Q B = 400 mL/min, Q D = 500 mL/min)P RO DUC T SSPOT on:High selectivepermeability for middle moleculesImproved removalof phosphateThe benefits of the advanced fibre design isnot limited to better middle molecule removal. The reduced transmembrane resistance of the FX CorDiax improves the removal of lowm olecular weight substances, e.g. parison of aqueous in-vitro clearances of phosphate(Q B = 300 mL/min, Q D = 500 mL/min). Investigations carried outS P T I N L I N E S t e aS P T S u p e r i oMembranes, such as Helixone ®, which have a high endotoxin retention capacity, protect the patient from inflammation , particularly when ultrapure dialysate is not available.1 SPOT on: Absence of endotoxins minimises inflammation. Reduced cardiovascularrisk factors.Support regionalbumin.I nflammation A naemiaA myloidosisby up to 50%.I mmuneof IFN-γDialysate Inlet PressureBlood OutletPressure26050403020100200190180170160150140β2-microglobulin Q B = 250 mL/min, Q D = 500 mL/min UreaProtect your PatientClinical practice guidelines in Europe recommend the use of High-Flux haemodialysers:Guidelines recommend High-Flux dialysers 1 T attersall J., Nephrol Dial Transplant (2010); 25: 1230–1232.2 M actier R. et al., Renal Association 2009, Renal Association Clinical Practice Guidelines. Haemodialysis membranes(Guidelines 4.1 to 4.5). /clinical/GuidelinesSection/Haemodialysis.aspx. Accessed 2 Dec. 2012.S P T4, 5, 6210 µmS P TC l i n i c a l B e n e fi t s o f t h e R e m o v2SPOT on:I mproved anaemiacontrol.6, 7Reduced inflammation.2 R educed risk of CVDdue to minimising the risk factors.Anaemia management – it was shown thatHigh-Flux membranes improved control of anaemia in EPO hypo-responsive patients while allowing a progressive reduction in the exogenous EPO dose by 25 to 45 %.7 Hence, High-Flux membranes offer the potential to reduce EPO costs.4041Head office: Fresenius Medical Care Deutschland GmbH · 61346 Bad Homburg v. d. H. · Germany Phone: +49 (0) 6172-609-0 · Fax: +49 (0) 6172-609-2191 F 0006435 M T -E N (1.0 B G -p p p p 08.14) © C o p y r i g h t 2012 F r e s e n i u s M e d i c a l C a r e D e u t s c h l a n d G m b H c e r t i f i e d , P E F C /04-31-0000。

南昌大学学报(医学版)2021年第 61卷第 1期Journal of Nanchang University(Medical Sciences)2021,Vol.61No.143血清可溶性生长刺激表达基因2在慢性心力衰竭患者诊断与预后评估中的应用刘壮壮，黄宇理(蚌埠医学院第一附属医院心血管内科，安徽蚌埠233000)摘要：目的探讨血清可溶性生长刺激表达基因2蛋白(sST2)在慢性心力衰竭(CHF)患者诊断与预后评估中的应用价值。

方法选取2018年12月至2019年5月蚌埠医学院第一附属医院心血管内科的CHF患者107例；基于NYHA心功能分级将其分为3组，即II级组(19例)、III级组(64例)和N级组(24例)；检测各组血清氨基末端脑钠肽前体(NT-proBNP)和sST2水平、6分钟步行实验(6MWT)、左室射血分数(LVEF)和左室质量指数(LVMI)；分析sST2水平与患者心功能分级、性别、年龄及上述指标的相关性。

结果sST2、6MWT、NT-proBNP水平随着心功能分级的提高而升高(均P<0.01),LVEF随着心功能分级的提高而降低(P<0.01)；sST2水平与患者心功能分级、NT-proBNP、LVMI和6MWT呈正相关(=0.741、r=0.840、r=0.378、r=0.843,均 P<0.01),与LVEF呈负相关(r=-0.657,P<0.01),与性别、年龄无关(r=0.051、r=0.064,P>0.05)。

结论血清sST2水平与CHF 患者的严重程度、预后存在关联，可作为CHF诊断与预后评估的标志物。

关键词：慢性心力衰竭；可溶性生长刺激表达基因2蛋白；诊断；预后中图分类号：R541文献标志码：A文章编号：2095-4727(2021)01-0043-04DOI：10.13764/ki.ncdm.2021.01.009Value of Serum Soluble Growth Stimulation Expressedgene2in Evaluation of Diagnosis andPrognossofChroncHeartFalureLIU Zhuang-zhuang,HUANG Yu-li{Department of Cardiology,the First Affiliated Hospital of BengbuMedical College^Bengbu233000?China)ABSTRACT：Objective Toexplorethevalueofserumsolublegrowthstimulationexpressedgene 2(sST2)in the evaluation of diagnosis and prognosis of chronic heart failure(CHF).Methods A totalof107CHFpatientstreatedintheFirstA f iliated HospitalofBengbu MedicalCo l egefrom December2018to May2019wereselectedinthisstudy.Accordingtothe NYHA classification, the patients were divided into three groups:grade I(n=19),grade I(n=64)and grade IV(n=24).Serum N-terminalpro-brainnatriureticpeptide(NT-ProBNP)andsST2levels,6-minutewalktest6MWT)distance,leftventricularejectionfraction(LVEF),andleftventricular massindex (LVMI)wereexaminedina l patients.Furthermore,therelationshipsofsST2levelsto NYHA classification,gender,age and cardiac function parameters were analyzed.Results The sST2and NT-proBNPlevelsand6MWTdistanceincreasedbuttheLVEFdecreasedwiththeimprovement in NYHA classification(P<0.01).The sST2level was positively correlated with NYHAclassifi-收稿日期:2020-05-06基金项目：蚌埠医学院科研创新计划(Byycxzl823)作者简介：刘壮壮(1994—),男，硕士研究生，住院医师，主要从事心力衰竭的研究。

国际免疫学杂志2021年1月第44卷第1期丨m j hnmUn 〇U a n .2021,V 〇1.44，N 〇. 1• 71 ••综述•心肌缺血再灌注损伤中细胞焦亡的研究进展刘成兴林吉斌李大主华中科技大学同济医学院附属协和医院心内科，武汉43〇〇22 通信作者：李大主，E m a i l :lid a z h u h p @ s o h u . c o m ,电话：139****1110【摘要】细胞焦亡是近年来发现并被证实的一种新的细胞程序性死亡方式，它的特征是依赖半胱氨酸天冬氨酸酶丨（cysteinyl aspartate specific proteinase 1 ,caspase-l)并伴随大量炎症因子的释放。

细胞 焦亡参与了包括感染性疾病在内的多种疾病的病理生理过程作为一种新的调节性细胞死亡方式，近 年来细胞焦亡受到了广泛的关注。

新近研究发现，细胞焦亡也参与了心肌缺血再灌注损伤（myocardialiscliemia reperfusion injury,MIRI)过程，文摩:就M 丨R I 中细胞焦亡的研究进展进行综述.【关键词】细胞焦亡;心肌缺血再灌注损伤;炎性小体基金项目：国家自然科学基金（8〗670404,81700390)D O I ：10. 3760/cma.j. issn. 16734394.2021.01.012Research progress of cell pyroptosis in myocardial ischemia reperfusion injuryLiu Chengxing，Lin Jibin ,Li DazhuDepartment of Cardiology .Union Hospital ,Tongji Medical College ,Haazhong University o f Science and Technolo­gy ,Wuhan 430022, ChinaCorresponding author ： Li I)azhu , Email ： lidazkuhp@ sohu. com , Tel ： 13971091 1 10【Abstract 】 Cell pyroptosis is a newly found m o d e of regulated cell death and experimentally verified re-c-ently. I t i s characterized l )y i t s dependence on cysteinyl asparlale specific proteinase 1 (caspase-1 ) and the re­lease of a large numb e r of inflammatory factors. Pyroptosis i s involved in the pathophysiological process of m a n y diseases including infectious diseases. As a new way of regulatory cell death, pyroptosis has attracted extensive attention in recent years. Recent studies have found that i t participates iq the pathological processes of myocardi­al ischemia reperfusion injury ( M I R I ) . This review summarized the research progress of cell pyroptosis in MIRI.【Key words 】Cell pyroptosis; Myocardial ischemia reperfusion injury; InflammasomeFund program ： National Natural Science Foundation of China( 81670404,81700390)D O I ： 10. 3760/cma. j . issn. 16734394. 2021.01.012上的模式识别受体（pattern recognition receptor ,P R R)识别并诱导相应的炎症反应过程，这些炎症细胞包括单核/巨噬细胞、中性粒细胞和树突状细胞 等夂。

甲哌卡因Mepivacaine【其它名称】甲哌酰卡因、卡波卡因、盐酸甲哌卡因、豁酸卡波卡因、Carbocaine、Mepivacaine Hydrochloride、Mepivacainum、Polocaine【临床应用】适用于腹部、四肢及会阴部手术等，常用作浸润麻醉、周围神经阻滞、硬膜外和骶管阻滞等。

【药理】1．药效学本药为酰胺类局部麻醉药，作用与利多卡斟相似或稍强，约为普鲁卡因的2倍。

本药起效迅速，麻醉持续时间持久，且不扩张血管，使用时可不加。

肾上腺素。

2．药动学本药用于硬膜外麻醉时5-15分钟起效。

浸润麻醉时作用持续45-90分钟，硬膜外阻滞时持续6-180分钟。

达峰时间在神经阻滞时为30-60分钟，浸润麻醉时为30分钟。

当血药浓度达到5-lOμg／ml时，对中枢神经及心血管有毒性作用。

总蛋白结合率为75％，可分布到全身各组织中，其中肝、肺、心及脑组织中浓度最高。

在肝脏中迅速代谢后，经肾排泄，主要为代谢产物，原形不足5％-10％。

也可从胆汁中排泄，但最终经肠肝循环从尿中排出。

母体化合物的清除半衰期，成人为1.9～3.2小时，新生儿为8.7-9小时。

【注意事项】1．禁忌症对本药或其它酰胺类麻醉药过敏者(国外资料)。

2．慎用(1)心脏疾病、高血压性血管病(Hypertenswe vascular disease)、低血压。

(2)肝肾疾病。

(以上均为国外资料)3．药物对妊娠的影响本药可通过眙盘影响胎儿。

产科麻醉时如果使用本药，婴儿出生后心动过缓和酸中毒的发生率会增加，国外尚有引起婴儿室性心动过速和死亡的个案报道。

美国FDA对本药的妊娠危险性分级为C级。

4．药物对哺乳的影响本药是否经乳汁分泌尚不明确。

【不良反应】本药引起的全身反应与其它局麻药相似，偶见惊厥、肌肉抽搐、虚脱和低血压，并可能致死。

本药还可使正常心率减慢，有发生Ⅰ度房室传导阻滞及过敏反应的个案报道。

[国外不良反应参考]1．血液系统有研究表明，本药可促发急性血卟啉病。

专利名称：去细胞化的脂肪组织专利类型：发明专利
发明人：L·E·弗林
申请号：CN201080064286.X 申请日：20101217
公开号：CN102933705A
公开日：
20130213
专利内容由知识产权出版社提供
摘要：本发明提供了一种对脂肪组织去细胞化的方法，包括将脂肪组织在含有一种或者多种的酶的酶解液中进行一次或者多次的培养，还有一次或者多次的溶剂萃取，其中，得到了包括三维结构很好保留的胞外基质的去细胞化脂肪组织。

本发明还提供了一种包括三维结构很好保存的胞外基质的去细胞化脂肪组织，和生物支架、微载体珠，和包括去细胞化脂肪组织的涂层。

申请人：金斯顿女王大学
地址：加拿大安大略省
国籍：CA
代理机构：永新专利商标代理有限公司
代理人：过晓东
更多信息请下载全文后查看。

魔卡素
魔卡素——存储青春的魔素MAGICSERUM魔丽世嘉护肤专家联合瑞士EPFL大学及瑞士国家科研能力中心(NCCR) ，从纯天然草本植物中研发出震惊美容界之抗衰老元素魔卡素，开启了瑞士抗衰老植物活性元素的先河，突破美容新概念，该项技术已涉及到医学界的各个领域和各个学科，它为美容界的发展带来了革命性的突破，21世纪伴随着分子生物学、生物化学技术的飞速发展，魔卡素类物质具有极强的活性和多样性，是世界生物学界、医学界、药学界研究开发的热点，生物活性魔卡素将在世界范围内引起关注，21世纪将是魔卡素的世纪。

从植物精华中提取的抗衰老元素魔卡素在抗衰老效果得到了全世界的一致认可。

经历反复使用验证，其抗衰老效果让无数的达官贵族、名人及明星实现了延缓青春、绽放美丽的不老传说。

全面解决肌肤问题苏醒疲惫细胞肌肤焕然一新
促进胶原蛋白生成恢复饱满肌
减少表情肌牵拉改善假性皱纹
抗氧化 2%魔卡素可提高抗氧化效果达
美白、击退斑块
涂于皮肤10秒钟即被吸收深层发挥补水作用，用后肌肤好水嫩哦！肌肤对营养
的吸收度会大大的提升
美颜功效：
✧对肌肤吸收功能是一次革命的突破！可提高肌肤吸收护肤品中的有效成份达10
倍以上,有吸收才有效果！
✧能有效供给肌肤细胞能量，促进细胞分裂频率比成熟细胞强
200 倍，全面启动皮肤细胞的分裂和活化；
✧2%魔卡素可提高抗氧化效果达53%.可抑制酪氨酸酶的活性，避免
黑色素生成；
✧亲肤性极佳，涂于皮肤10秒钟即被吸收，可深入肌肤底层，发挥保湿
作用，提高皮肤持久保水能力；
强化自身免疫力，5%魔卡素可提高淡化疤痕效果达12%以上。

细胞培养用青霉素-链霉素产品简介：细胞培养用青霉素-链霉素(Penicillin-Streptomycin for Cell Culture)为粉剂，是最常用的细胞培养用抗生素(即通常所谓的双抗)。

在细胞培养液中推荐的青霉素的工作浓度为100U/ml ，链霉素的工作浓度为0.1mg/ml 。

一个包装的细胞培养用青霉素-链霉素可以配制80L 细胞培养液。

保存条件：室温保存。

4ºC 保存可以使用更长时间。

注意事项：开瓶后需防止受潮。

本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。

为了您的安全和健康，请穿实验服并戴一次性手套操作。

使用说明：细胞培养用青霉素-链霉素可以参考如下两种方法之一使用：1. 配制细胞培养液时加入细胞培养用青霉素-链霉素，然后再过滤除菌：配制细胞培养液时按照青霉素的工作浓度为100U/ml ，链霉素的工作浓度为0.1mg/ml 进行配制，配制完成后过滤除菌即可使用。

2. 配制青霉素-链霉素溶液(100X)母液，然后再添加到细胞培养液中：按照青霉素的含量为10KU/ml ，链霉素的含量为10mg/ml ，配制青霉素-链霉素溶液(100X)母液。

过滤除菌后即可按照100倍稀释加入到细胞培养液中使用。

配制的母液可以-20ºC 冻存。

使用本产品的文献：1. Wang PH, Gu ZH, Wan DH, Zhang MY , Weng SP, Yu XQ, He JG. The shrimp NF-κB pathway is activated by white spot syndrome virus (WSSV) 449 to facilitate the expression of WSSV069 (ie1), WSSV303 and WSSV371.PLoS One. 2011;6(9):e24773.2. Xia M, Zhu Y . Signaling pathways of ATP-induced PGE2 release inspinal cord astrocytes are EGFR transactivation-dependent. Glia. 2011 Apr;59(4):664-74. 3. He YH, Song Y , Liao XL, Wang L, Li G, A lima, Li Y , Sun CH. Thecalcium-sensing receptor affects fat accumulation via effects on antilipolytic pathways in adipose tissue of rats fed low-calcium diets. J N utr. 2011 Nov;141(11):1938-46. 4. Liu XY , Wei W, Wang CL, Yue H, Ma D, Zhu C, Ma GH, Du YGApoferritin-camouflaged Pt nanoparticles: surface effects on cellular uptake and cytotoxicity. J. Mater. Chem., 2011,21, 7105-7110. 5. Wang MN, Liu XY , Cao CB, Shi C Synthesis of band-gap tunable Cu –In –S ternary nanocrystals in aqueous solution RSC Adv. 2012 Feb; 7:2666-70. 6. Fan H, Yang L, Fu F, Xu H, Meng Q, Zhu H, Teng L, Yang M, Zhang L,Zhang Z, Liu K Cardio protective effects of salvianolic Acid a on myocardial ischemia-reperfusion injury in vivoand in vitro. Evid Based Complement Alternat Med. 2012;2012:508938. 7. Zhang J, Tang L, Shen L, Zhou S, Duan Z, Xiao L, Cao Y , Mu X, Zha L,Wang H High level of WA VE1 expression is associated with tumor aggressiveness and unfavorableprognosis of epithelial ovarian cancer. Gynecol Oncol. 2012 Oct;127(1):223-30.8. Zhang Y , Zhang Y , Chen M, Yan J, Ye Z, Zhou Y , Tan W, Lang M.Surface properties of amino-functionalized poly(ε-caprolactone) membranes and the improvement of humanmesenchymal stem cell behavior. J Colloid Interface Sci. 2012 Feb 15;368(1):64-9. 9. Jiang M, Gan L, Zhu C, Dong Y , Liu J, Gan Y . Cationic core-shellliponanoparticles for ocular gene delivery. Biomaterials. 2012 Oct; 33(30):7621-30. 10. Chai YY , Wang F, Li YL, Liu K, Xu H. Antioxidant Activities ofStilbenoids from Rheum emodi Wall. Evid Based Complement Alternat Med. 2012;2012:603678. 11. Guo S, Sun X, Cheng J, Xu H, Dan J, Shen J, Zhou Q, Zhang Y , Meng L,Cao W, Tian Y . Apoptosis of THP-1 macrophages induced by protoporphyrin IX-mediated sonodynamic therapy. Int J Nanomedicine. 2013;8:2239-46. 12. Wang S, Luo Y , Zeng S, Luo C, Yang L, Liang Z, Wang Y .Dodecanol-poly(D,L-lactic acid)-b-poly (ethylene glycol)-folate (Dol- PLA-PEG-FA) nanoparticles: evaluation of cell cytotoxicity and selecting capability in vitro. Colloids Surf B Biointerfaces. 2013 Feb 1;102:130-5.碧云天生物技术/Beyotime Biotechnology 订货热线: 400-1683301或800-8283301 订货e-mail :****************** 技术咨询: ***************** 网址: 碧云天网站 微信公众号13.Zhou S, Tang L, Wang H, Dai J, Zhang J, Shen L, Ng SW, Berkowitz RS.Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer. Gynecol Oncol. 2013 Oct;131(1):69-76.14.Xia M, Zhu Y. FOXO3a Involvement in the Release of TNF-α Stimulatedby ATP in Spinal Cord Astrocytes. J Mol Neurosci. 2013 Nov;51(3):792-804.15.Zhou DH, Wang X, Yang M, Shi X, Huang W, Feng Q. Combination ofLow Concentration of (-)-Epigallocatechin Gallate (EGCG) and Curcumin Strongly Suppresses the Growth of Non-Small Cell Lung Cancer in Vitro and in Vivo through Causing Cell Cycle Arrest. Int J Mol Sci. 2013 Jun 5;14(6):12023-36.16.Jiang XY, Lu DB, Jiang YZ, Zhou LN, Cheng LQ, Chen B.PGC-1αprevents apoptosis in adipose-derived stem cells by reducing reactive oxygen species production in adiabetic microenvironment. Diabetes Res Clin Pract. 2013 Jun;100(3):368-75.17.Zhu Q, Guo T, Xia D, Li X, Zhu C, Li H, Ouyang D, Zhang J, Gan Y.Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration.J Pharm Pharmacol. 2013 Aug;65(8):1107-17.18.Hu HJ, Lin XL, Liu MH, Fan XJ, Zou WW. Curcumin mediatesreversion of HGF-induced epithelial-mesenchymal transition via inhibition of c-Metexpression in DU145 cells. Oncol Lett. 2016 Feb;11(2):1499-1505.19.Sun C, Feng SB, Cao ZW, Bei JJ, Chen Q, Zhao WB, Xu XJ, Zhou Z, YuZP, Hu HY. Up-Regulated Expression of Matrix Metalloproteinases in Endothelial Cells Mediates PlateletMicrovesicle-Induced Angiogenesis.CELL PHYSIOL BIOCHEM . 2017;41(6):2319-2332.20.Wang J, Zeng H, Li H, Chen T, Wang L, Zhang K, Chen J, Wang R, Li Q,Wang S. MicroRNA-101 Inhibits Growth, Proliferation and Migration and Induces Apoptosis of BreastCancer Cells by Targeting Sex-Determining Region Y-Box 2. CELL PHYSIOL BIOCHEM .2017;43(2):717-732.21.Jiang W, Huang W, Chen Y, Zou M, Peng D, Chen D. HIV-1Transactivator Protein Induces ZO-1 and Neprilysin Dysfunction in Brain Endothelial Cellsvia the Ras Signaling Pathway. Oxid Med Cell Longev . 2017;2017:3160360.22.Li W, Yang Y, Ba Z, Li S, Chen H, Hou X, Ma L, He P, Jiang L, Li L, HeR, Zhang L, Feng D. MicroRNA-93 Regulates Hypoxia-Induced Autophagy by Targeting ULK1. Oxid Med Cell Longev .2017;2017:2709053.23.Hu SY, Zhang Y, Zhu PJ, Zhou H, Chen YD. Liraglutide directly protectscardiomyocytes against reperfusion injury possibly via modulation of intracellular calcium homeostasis. J Geriatr Cardiol . 2017 Jan;14(1):57-66.24.Li W, Wang Z, Zha L, Kong D, Liao G, Li H. HMGA2 regulatesepithelial-mesenchymal transition and the acquisition of tumor stem cellproperties through TWIST1 in gastric cancer. Oncol Rep . 2017 Jan;37(1):185-192.25.Tang J, Dong Q. Knockdown of TREM-1 suppresses IL-1β-inducedchondrocyte injury via inhibiting the NF-κB pathway. BIOCHEM BIOPH RES CO . 2017 Jan 22;482(4):1240-1245.26.Yang T, Cheng J, Yang Y, Qi W, Zhao Y, Long H, Xie R, Zhu B. S100BMediates Stemness of Ovarian Cancer Stem-Like Cells Through Inhibiting p53. Stem Cells . 2017 Feb;35(2):325-336.27.Sun K, Liu F, Wang J, Guo Z, Ji Z, Yao M. The effect of mechanicalstretch stress on the differentiation and apoptosis of human growthplate chondrocytes. IN VITRO CELL DEV-AN . 2017 Feb;53(2):141-148. 28.Peng L, Wang R, Shang J, Xiong Y, Fu Z. Peroxiredoxin 2 is associatedwith colorectal cancer progression and poor survival of patients.ONCOTARGET . 2017 Feb 28;8(9):15057-15070.29.Li L, Guan Q, Dai S, Wei W, Zhang Y. Integrin β1 Increases Stem CellSurvival and Cardiac Function after Myocardial Infarction. Front Pharmacol . 2017 Mar 17;8:135.30.Sui Y, Yao H, Li S, Jin L, Shi P, Li Z, Wang G, Lin S, Wu Y, Li Y, HuangL, Liu Q, Lin X. Delicaflavone induces autophagic cell death in lung cancer via Akt/mTOR/p70S6K signalingpathway. J MOL MED . 2017 Mar;95(3):311-322.31.Zuo S, Ge H, Li Q, Zhang X, Hu R, Hu S, Liu X, Zhang JH, Chen Y,Feng H. Artesunate Protected Blood-Brain Barrier via Sphingosine 1 Phosphate Receptor1/Phosphatidylinositol 3 Kinase Pathway After Subarachnoid Hemorrhage in Rats. Mol Neurobiol . 2017 Mar;54(2):1213-1228.32.Shen XQ, Geng YM, Liu P, Huang XY, Li SY, Liu CD, Zhou Z, Xu PP.Magnitude-dependent response of osteoblasts regulated by compressive stress. SCI REP-UK . 2017 Mar 20;7:44925.33.Yang R, Wei L, Fu QQ, You H, Yu HR. SOD3 Ameliorates Aβ25-35-Induced Oxidative Damage in SH-SY5Y Cells by Inhibiting the Mitochondrial Pathway. Cell Mol Neurobiol . 2017 Apr;37(3):513-525.34.Lin H, Zhao L, Ma X, Wang BC, Deng XY, Cui M, Chen SF, Shao ZW.Drp1 mediates compression-induced programmed necrosis of rat nucleus pulposus cells by promoting mitochondrial translocation of p53 and nuclear translocation of AIF. BIOCHEM BIOPH RES CO . 2017 May 20;487(1):181-188.35.Zhang C, Zhou G, Cai C, Li J, Chen F, Xie L, Wang W, Zhang Y, Lai X,Ma L. Human umbilical cord mesenchymal stem cells alleviate acute myocarditis by modulatingendoplasmic reticulum stress and extracellular signal regulated 1/2-mediated apoptosis. Mol Med Rep . 2017 Jun;15(6):3515-3520.36.Zhang EF, Hou ZX, Shao T, Yang WW, Hu B, Wang XX, Zhang ZX,Huang Y, Xiong LZ, Hou LC. Combined administration of a sedative dose sevoflurane and 60% oxygen reduces inflammatoryresponses to sepsis in animals and in human PMBCs. Am J Transl Res . 2017 Jun 15;9(6):3105-3119.37.Shi S, Zhong D, Xiao Y, Wang B, Wang W, Zhang F, Huang H.Syndecan-1 knockdown inhibits glioma cell proliferation and invasion by deregulating a c-src/FAK-associated signaling pathway.ONCOTARGET . 2017 Jun 20;8(25):40922-40934.38.Lin XL, Hu HJ, Liu YB, Hu XM, Fan XJ, Zou WW, Pan YQ, Zhou WQ,Peng MW, Gu CH. Allicin induces the upregulation of ABCA1 expression via PPARγ/LXRαsignaling in THP-1macrophage-derived foam cells. Int J Mol Med . 2017 Jun;39(6):1452-1460.39.Peng K, Yang L, Wang J, Ye F, Dan G, Zhao Y, Cai Y, Cui Z, Ao L, Liu J,Zou Z, Sai Y, Cao J. The Interaction of Mitochondrial Biogenesis and Fission/Fusion Mediated by PGC-1αRegulatesRotenone-Induced Dopaminergic Neurotoxicity. Mol Neurobiol . 2017 Jul;54(5):3783-3797.40.Liu Z, Zeng W, Wang S, Zhao X, Guo Y, Yu P, Yin X, Liu C, Huang T. Apotential role for the Hippo pathway protein, YAP, in controlling proliferation, cell cycleprogression, and autophagy in BCPAP and KI thyroid papillary carcinoma cells. Am J Transl Res . 2017 Jul 15;9(7):3212-3223.41.Ge Z, Diao H, Yu M, Ji X, Liu Q, Chang X, Wu Q. Connexin 43mediates changes in protein phosphorylation in HK-2 cells during chronic cadmiumexposure. ENVIRON TOXICOL CHEM . 2017 Jul;53:184-190.42.Zhu YM, Gao X, Ni Y, Li W, Kent TA, Qiao SG, Wang C, Xu XX, ZhangHL. Sevoflurane postconditioning attenuates reactive astrogliosis and glial scar formation afterischemia-reperfusion brain injury.Neuroscience . 2017 Jul 25;356:125-141.43.Wei JL, Fang M, Fu ZX, Zhang SR, Guo JB, Wang R, Lv ZB, Xiong YF.Sestrin 2 suppresses cells proliferation through AMPK/mTORC1 pathway activation in colorectalcancer. ONCOTARGET . 2017 Jul 25;8(30):49318-49328.44.Zhao L, Yang Y, Yin S, Yang T, Luo J, Xie R, Long H, Jiang L, Zhu B.CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes.ONCOTARGET . 2017 Jul 10;8(37):62217-62230.45.Fu QQ, Wei L, Sierra J, Cheng JZ, Moreno-Flores MT, You H, Y u HR.Olfactory Ensheathing Cell-Conditioned Medium Reverts Aβ25-35-Induced Oxidative Damage in SH-SY5Y Cells by Modulating the Mitochondria-Mediated Apoptotic Pathway. Cell Mol Neurobiol . 2017 Aug;37(6):1043-1054.46.Wang T, Liu YP, Wang T, Xu BQ, Xu B. ROS feedback regulates themicroRNA-19-targeted inhibition of the p47phox-mediated LPS-induced inflammatory response. BIOCHEM BIOPH RES CO . 2017 Aug 5;489(4):361-368.47.Zhu Y, Wang L, Y u H, Yin F, Wang Y, Liu H, Jiang L, Qin J. In situgeneration of human brain organoids on a micropillar array. Lab Chip .2017 Aug 22;17(17):2941-2950.48.Liu C, Liu J, Hao Y, Gu Y, Yang Z, Li H, Li R.6,7,3',4'-Tetrahydroxyisoflavone improves the survival of whole-body-irradiated mice viarestoration of hematopoietic function. Int J Radiat Biol . 2017 Aug;93(8):793-802.49.Liao Q, Zhang R, Wang X, Nian W, Ke L, Ouyang W, Zhang Z. Effect offluoride exposure on mRNA expression of cav1.2 and calcium signal pathway apoptosisregulators in PC12 cells. ENVIRON TOXICOL CHEM . 2017 Sep;54:74-79.2 / 3ST488 细胞培养用青霉素-链霉素400-1683301/800-8283301碧云天/Beyotime50.Pan S, Cui Y, Dong X, Zhang T, Xing H. MicroRNA-130b attenuatesdexamethasone-induced increase of lipid accumulation in porcinepreadipocytes by suppressing PPAR-γexpression.ONCOTARGET . 2017 Sep 27;8(50):87928-87943.51.Zhong Y, Jin C, Gan J, Wang X, Shi Z, Xia X, Peng X. Apigeninattenuates patulin-induced apoptosis in HEK293 cells by modulating ROS-mediatedmitochondrial dysfunction and caspase signal pathway.Toxicon . 2017 Oct;137:106-113.52.Yin L, Huang D, Liu X, Wang Y, Liu J, Liu F, Yu B. Omentin-1 effectson mesenchymal stem cells: proliferation, apoptosis, and angiogenesis in vitro. Stem Cell Res Ther . 2017 Oct 10;8(1):224.53.Tang X, Zha L, Li H, Liao G, Huang Z, Peng X, Wang Z. Upregulationof GNL3 expression promotes colon cancer cell proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway. Oncol Rep . 2017 Oct;38(4):2023-2032.54.Wu S, Wu F, Jiang Z. Identification of hub genes, key miRNAs andpotential molecular mechanisms of colorectalcancer. Oncol Rep . 2017 Oct;38(4):2043-2050.55.Wang X, Chen G, Huang C, Tu H, Zou J, Yan J. Bone marrow stemcells-derived extracellular matrix is a promising material.ONCOTARGET . 2017 Oct 9;8(58):98336-98347.56.Sun R, Yin L, Zhang S, He L, Cheng X, Wang A, Xia H, Shi H. SimpleLight-Triggered Fluorescent Labeling of Silica Nanoparticles for Cellular ImagingApplications. Chemistry . 2017 Oct 9;23(56):13893-13896. 57.Lin H, Ma X, Wang BC, Zhao L, Liu JX, Pu FF, Hu YQ, Hu HZ, ShaoZW. Edaravone ameliorates compression-induced damage in rat nucleus pulposus cells. Life Sci . 2017 Nov 15;189:76-83.58.Sun G, Sui X, Han D, Gao J, Liu Y, Zhou L. TRIM59 promotes cellproliferation, migration and invasion in human hepatocellular carcinomacells. Pharmazie . 2017 Nov 1;72(11):674-679.59.Zhu Y, Wang L, Yin F, Yu Y, Wang Y, Shepard MJ, Zhuang Z, Qin J.Probing impaired neurogenesis in human brain organoids exposed to alcohol. INTEGR BIOL-UK . 2017 Dec 11;9(12):968-978.60.Shan Y, Wang Y, Li J, Shi H, Fan Y, Yang J, Ren W, Y u X. Biomechanicalproperties and cellular biocompatibility of 3D printed tracheal graft.Bioprocess Biosyst Eng . 2017 Dec;40(12):1813-1823.61.Liu H, Wu B, Ge Y, Huang J, Song S, Wang C, Yao J, Liu K, Li Y, Li Y,Ma X. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesionkinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines. BIOORG MED CHEM LETT . 2017 Dec 15;25(24):6313-6321.62.Lin XL,Liu M,Liu Y,Hu H,Pan Y,Zou W,Fan X,Hu X. Transforminggrowth factor β1 promotes migration and invasion in HepG2 cells: Epithelial-to-mesenchymal transition via JAK/STA T3 signaling. Int J Mol Med. 2018 Jan;41(1):129-136.63.Duan C,Liu Y,Li Y,Chen H,Liu X,Chen X,Y ue J,Zhou X,Yang J.Sulfasalazine alters microglia phenotype by competing endogenous RNA effect of miR-136-5p and long non-coding RNA HOTAIR in cuprizone-induced demyelination. Biochem Pharmacol. 2018 Sep;155:110-123.64.Zhou X,Li T,Chen Y,Zhang N,Wang P,Liang Y,Long M,Liu H,Mao J,LiuQ,Sun X,Chen H. Mesenchymal stem cell-derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway. Int J Oncol. 2019 May;54(5):1843-1852.65.Zheng W,Liu C. The cystathionine γ-lyase/hydrogen sulfide pathwaymediates the trimetazidine-induced protection of H9c2 cells against hypoxia/reoxygenation-induced apoptosis and oxidative stress. Anatol J Cardiol. 2019 Sep;22(3):102-111.66.Lou K,Huang P,Ma H,Wang X,Xu H,Wang W. Orlistat increases arsenitetolerance in THP-1 derived macrophages through the up-regulation of ABCA1. Drug Chem Toxicol. 2019 Oct 31:1-9.67.Liang S,Wang F,Bao C,Han J,Guo Y,Liu F,Zhang Y. BAG2 amelioratesendoplasmic reticulum stress-induced cell apoptosis in Mycobacterium tuberculosis-infected macrophages through selective autophagy.Autophagy. 2019 Nov 11:1-15.68.Yuan K,Lai C,Wei L,Feng T,Yang Q,Zhang T,Lan T,Yao Y,XiangG,Huang X. The Effect of Vascular Endothelial Growth Factor on Bone Marrow Mesenchymal Stem Cell Engraftment in Rat Fibrotic Liver upon Transplantation. Stem Cells Int. 2019 Dec 4;2019:5310202.Version 2021.11.04碧云天/Beyotime 400-1683301/800-8283301 ST488 细胞培养用青霉素-链霉素 3 / 3。

清丽雅思——鱼鳞病护肤专家“清丽雅思”介绍：“清丽雅思”系列护肤品是治愈鱼鳞病特效疗法——“张建疗法”的后期专用护肤产品。

清丽雅思系列护肤品由“北京张建鱼鳞病研究院”专项研发，依据独家配方，采用天然中草药植物精华成份，合理复方配比，经现代科技工艺精炼、提取而成。

主要针对鱼鳞病肌肤、极度干燥肌肤除有抑制皮屑生长、强效保湿功能外，于其他护肤品最大的不同在于，“清丽雅思”些列产品中的中草药成份，可抑制、降低引发鱼鳞病发病的基因显性概率，起到防止复发和降低遗传的作用。

“清丽雅思”最大功能特色：众所周知，鱼鳞病是一组遗传性角化障碍性皮肤疾病，根据国内外专家的研究论证，各型鱼鳞病的致病都源于基因的异常、突变，并且有研究结论：虽然生物体的一切遗传性状都受基因控制，但是基因并不等于性状，不同基因型的个体在不同的环境条件下可以产生不同的表现型。

根据中医所讲，先天禀赋不足，后天添补的原理，“张建疗法”在治疗和“清丽雅思”护肤品中所采用的中药药物都具备了改善体内环境、降低突变基因表达的功效。

这也是与普通保湿护肤品或复方乳酸软膏、鱼肝油乳膏等外用药物只是保湿、抗皲裂最大的不同，不仅解决了鱼鳞病患者反复复发的痛苦，也可大大降低后代继续发生鱼鳞病的担忧，实是鱼鳞病患者最佳的选择。

“清丽雅思”分型介绍：【基础护肤产品（普通型、特配型、婴儿型、部位型）】特有专利配方中独特的保湿因子可使鱼鳞病患者及干性肌肤不再起鳞屑。

通常鱼鳞病患者会使用激素类的药膏使皮肤达到保湿，去鳞的作用，但长期使用副作用大，易形成黑斑、硬皮，产生抗药性使鳞屑越治越重；而甘油是市面上常用的保湿产品，但其因有酒精成份吸收水份，空气湿润的情况下，皮肤保湿效果比较好，但空气干燥的情况下，甘油会吸收皮肤的水份，从而造成皮肤比之前更加的粗糙干燥。

清丽雅思护肤品富含丰富的营养滋润成份能迅速补充水份，其特殊专利配方能锁住肌肤营养和水份，促进皮下血液循环、渗透至肌肤深层，增强肌肤弹性，且有效的抑制鱼鳞病患者鳞屑在生。

探讨经皮冠状动脉介入治疗缺血性心肌病合并严重心功能不全患者的临床疗效发布时间：2022-03-14T08:49:55.674Z 来源：《中国医学人文》2022年1期作者：姜玉库李绅源、朱丹、张麟、孙璐、王佳[导读] 探讨分析对缺血性心肌病合并严重心功能不全患者采用经皮冠状动脉介入治疗的临床疗效。

方法本次研究对象均选自我院2019年11月到2021年5月期间收治的缺血性心肌病合并严重心功能不全患者共72例，按照随机数字表法对患者分组，设定其中接受经皮冠状动脉介入治疗的36例为A组，其余36例为B组采用常规药物治疗，比较对两组的治疗效果。

姜玉库李绅源、朱丹、张麟、孙璐、王佳黑龙江省鸡西市人民医院 158100【摘要】目的探讨分析对缺血性心肌病合并严重心功能不全患者采用经皮冠状动脉介入治疗的临床疗效。

方法本次研究对象均选自我院2019年11月到2021年5月期间收治的缺血性心肌病合并严重心功能不全患者共72例，按照随机数字表法对患者分组，设定其中接受经皮冠状动脉介入治疗的36例为A组，其余36例为B组采用常规药物治疗，比较对两组的治疗效果。

结果比较两组的心功能指标改善情况，A组好于B组（P＜0.05）；比较两组的心绞痛分级，A组低于B组（P＜0.05）。

结论根据本次研究的结果可以确认，对缺血性心肌病合并严重心功能不全患者采用探讨经皮冠状动脉介入治疗的效果更为理想，能够有效改善患者的心功能，缓解患者的心绞痛症状，有必要大力推广。

【关键词】缺血性心肌病；严重心功能不全；经皮冠状动脉介入治疗；治疗效果；对比分析 [Abstract] Objective To explore and analyze the clinical efficacy of percutaneous coronary intervention in patients with ischemic cardiomyopathy complicated with severe cardiac insufficiency. Methods a total of 72 patients with ischemic cardiomyopathy complicated with severe cardiac insufficiency treated in our hospital from November 2019 to may 2021 were selected. The patients were divided into groups according to the random number table method 36 cases of coronary intervention were group A and the other 36 cases were group B. routine drug treatment was used to compare the therapeutic effects of the two groups. Results the improvement of cardiac function indexes between the two groups were compared, Group A was better than group B (P < 0.05), and the angina score of group A was lower than that of group B (P < 0.05). Conclusion according to the results of this study, it can be confirmed that the effect of percutaneous coronary intervention in patients with ischemic cardiomyopathy complicated with severe cardiac insufficiency is more ideal, which can effectively improve the cardiac function and alleviate the symptoms of angina pectoris, and it is necessary to popularize it.【 key words 】 ischemic cardiomyopathy; severe cardiac insufficiency; percutaneous coronary intervention; treatment effect; comparative analysis冠心病是一种临床比较常见的心脏疾病，虽然患者病情的发展，最终将引发患者出现缺血性心肌病，并导致患者伴发心功能不全，这不仅会使患者的生活质量大幅下降，还会危及到患者的生命【1】。

VisaBoostAbsorption Booster Advanced Dual Action Ultrasound and VibrationSC2800Enhance the absorption for better skincare benefitAdvanced synchronization of Ultrasound & Vibration The new Philips VisaBoost Ultrasound Facial Moisturizer helps your skin absorb skincare products better and faster, enhances skincare efficacy, reveals refreshed moisturized revived skin from inside out!Easy to useProbe can be washed directly under tap water1 charging for2 weeks usageInstant&lasting improvement of skincare efficacyRefresher & smoother skin right after the treatmentMore hydrated & moisturized skin after 6 weeks treatmentDual Action boost better absorptionAdvanced synchronization of Ultrasound and VibrationVibration gently stimulates skin's micro-circulationUltrasound encourages skin's natural cell renewalSafe to useIntelligent temperature detective controllerSuitable for all skin typesHighlightsDual Action SystemThe Dual Action System combining Ultrasound and Vibration has been especially designed to help skincare products be better absorbed into the deep layer of skin, where they can achieve maximum effect for healthy & dewy skin today and tomorrow.Easy to UseAfter each treatment, you can wash the probe directly under tap water and maintain it with protective cap.300/sec Vibration300/second vibration gently massages skin and stimulates micro-circulation, which further boosts absorption of skincare products and delivers a healthy glow continuously.5MHz UltrasoundUltrasound waves instantly dissolve skincare products into micro-molecules which are more easily transported into your skin's epidermis,stimulate skin's metabolism and encourage skin's natural renewal process.Temperature controllerThe device can automatically detect and adjust the temperature to keep the device working in best condition and maintain the moisture in your skin.Specialized&Flexible solution 3 min for regular treatment and 7 min for intensive treatment, you can use it with your preferred skincare products including serum,lotion or cream for 2 weeks continuously based on 1 charging.Suitable for all skin typesThe device is innovated to complement your current skincare routine & maximize skincare benefits no matter which kind of skin type you have, the effect of your moisturizing, whitening and anti-aging products will be improved.Short-term Visible Results>=93% of women tested agree the absorption effect of skincare products is better than by manual application and the speed is faster;94% of women tested feel skin is smoother instantly; 96% of women tested feel skin is refresher right after the treatment.Long-term Visible ResultsAfter 6 weeks treatment, 93% of women tested feel more moisturized skin, 94% of women tested feel skin is not so dry as before, 90% of women tested feel skin is revived.SpecificationsApplication areasFace: Cheeks, Chin, Forehead, NoseItems includedInstruction for use: Quick start guide, User manualPower adapter: 100 - 240 V adapterStand: Charging and storing standProtective cap: maintain and keep probe clean PowerPower system: Rechargeable battery Running time: 4-6 uses of 3/7 min each Automatic voltage: 100-240 VCharging time: 2 hr ServiceWarranty: 2-year limited warrantyDesignColor: Lovely pinkBenefitsAbsorption: Better absorption experienced by>=93% of usersPromoted skin renewal: lead by UltrasoundStimulated microcirculation: lead by 300/secvibrationEase of useBattery indicator: illuminated iconCordless: up to 4-6 use without chargingWaterproof: tip can be washed under tapwater directlyEasy handling: Ergonomic and elegant designExclusive and convenient stand: charging andstoring stand© 2019 Koninklijke Philips N.V.All Rights reserved.Specifications are subject to change without notice. Trademarks are the property of Koninklijke Philips N.V. or their respective owners.Issue date 2019‑07‑30 Version: 2.0.1。

【英文说明书】雅思敏抗衰产品使用说明书有效补水，增加面部肌肤弹性【产品简介】雅思敏抗衰产品由皮下注射器、不锈钢注射针和预装在注射器中的15ml玻尿酸凝胶融合磷酸盐缓冲生理盐水组成。

雅思敏抗衰产品经严格过滤消毒并盛放于玻璃质一次性注射器中；该注射器包装内部存有2支30mm注射针头，注射器顶端安置用以保证针头与注射器安全接头。

玻尿酸玻尿酸是一种高分子的多醣体，是由葡萄醛酸-N-乙酸氨基葡萄糖为双糖分子单位组成的直链高分子多醣，是一种皮肤组织中自然存在的物质。

雅思敏抗衰产品的Ph值以及渗透压度与皮肤数值一致，不相互排斥。

雅思敏抗衰产品不含乳胶成分，不属于动物源性产品。

CE0344雅思敏抗衰产品存放于一次性玻璃注射器内，打开包装即可正常使用。

CE0086 注射器泡沫包装内置放规格为30mm注射针2支（已经放射消毒）。

【剂量管理】医患间沟通保证透明，令患者明确注射部位、方法，并告知其产品性能、禁忌、不良影响以及副作用等。

注射疼痛感需要做出评定，视情况做局麻处理。

注射部位保证清洁无感染。

药物注射需以30口径针头进行皮下注射，针头与针管连接牢固并在针头顶端出现小滴液体后予以注射。

皮下注射建议分次进行。

针头变形立即替换更新。

注射剂量视情况而定，不可过量。

首次注射可作为修正治疗。

治疗部位经注射后，轻轻按摩局部，使进入皮内的药物均匀分布到皱纹及凹陷下。

告知患者以正确的化妆方式，并令其防止太阳直射、紫外线辐射，术后两周内避免蒸气浴。

【产品用途】雅思敏抗衰产品可对皮肤有效补水，增加面部肌肤弹性。

该产品对因年龄增长、恶劣环境所致的皮肤质酸流失致使面部皮肤衰老问题，可进行高效增补。

【禁忌症】对质酸有过敏反应的患者禁用。

【注意事项】该产品仅限于在国家正式批准的医疗机构中由具有相关专业医师资格的人员，严格按照产品使用说明书的要求进行使用。

由于玻尿酸是具黏性的胶状物质，故该产品不得注入于血管，以防血管堵闭造成栓塞或梗死。

如患者面部待注射部位出现肿胀、感染、过敏或具有慢性疾病，勿对其治疗。

艾璐卡sos急救精华备案编号
摘要：
1.艾璐卡sos 急救精华备案编号概述
2.艾璐卡sos 急救精华的主要成分
3.艾璐卡sos 急救精华的功效
4.艾璐卡sos 急救精华的使用方法
5.艾璐卡sos 急救精华的备案编号查询方式
正文：
艾璐卡sos 急救精华是一款备受关注的护肤品，其备案编号为【备案编号】。

下面我们将详细介绍这款精华的相关信息，帮助您更好地了解并使用它。

首先，我们来了解一下艾璐卡sos 急救精华的主要成分。

这款精华主要包含了【主要成分1】、【主要成分2】和【主要成分3】等，这些成分都具有优良的护肤效果，能够为肌肤提供充足的营养，并帮助修复受损肌肤。

艾璐卡sos 急救精华具有多种功效，包括【功效1】、【功效2】和【功效3】等。

使用这款精华，可以帮助您有效改善肌肤问题，提升肌肤的自我修复能力，使肌肤更加健康、亮丽。

在使用艾璐卡sos 急救精华时，您需要注意以下使用方法：【使用方法】。

正确的使用方法可以让精华发挥更好的效果，帮助您获得理想的护肤效果。

最后，如果您想了解艾璐卡sos 急救精华的备案编号，可以通过以下方式进行查询：【查询方式】。

查询备案编号可以帮助您确保购买的产品是正品，从而保障您的消费权益。

1例复发性胸腺瘤患者信迪利单抗治疗过程中出现心肌损伤的原因及处理李泞甫1，2，李智可1，2，陈旭澜1，2，皈燕21 川北医学院临床医学系，四川南充637000；2 川北医学院附属医院肿瘤科摘要：目的　总结复发性胸腺瘤患者信迪利单抗治疗过程中出现心肌损伤的原因，探讨有效处理方法。

方法　对1例复发性胸腺瘤信迪利单抗治疗过程中出现心肌损伤的患者临床资料作回顾性分析。

结果　患者2年前因胸腺瘤接受手术切除（R2切除） + 术后放射治疗，2年后出现复发伴肺转移，4周期CAP方案（环磷酰胺890 mg + 盐酸表柔比星130 mg + 顺铂80 mg）化疗后疾病进展。

与患者家属沟通后，予以信迪利单抗200 mg静脉注射（每三周一次）联合CAP化疗。

联合治疗1周期后，出现心肌酶谱升高、完全性右束支传导阻滞、眼睑下垂等心肌损伤症状，考虑为免疫性心肌炎。

使用甲强龙500 mg冲击治疗及其他对症支持治疗后，症状无明显好转，加用抗心律失常药物（胺碘酮、艾司洛尔）、吗替麦考酚酯及免疫球蛋白，但患者病情恶化于次日凌晨2时突发呼吸心脏骤停，抢救无效死亡。

结论　复发性胸腺瘤患者应用信迪利单抗治疗过程中可能发生心肌损伤，发生原因可能与胸腺为免疫器官及免疫治疗联合化疗的不良反应有关。

对于使用免疫治疗联合化疗的胸腺瘤患者应高度警惕，需动态监测心肌损伤指标，早期识别，分级治疗。

关键词：心肌损伤；心肌炎；免疫性心肌炎；药物不良反应；免疫检查点抑制剂doi：10.3969/j.issn.1002-266X.2023.33.018中图分类号：R730.51 文献标志码：A 文章编号：1002-266X（2023）33-0076-04恶性肿瘤和心血管疾病是全球范围内导致死亡的两大主要原因［1］。

免疫治疗、蒽环类药物及靶向药的应用明显改善患者预后，但其心血管不良反应已经成为影响肿瘤患者生存和预后的重要因素。

蒽环类药物引起心肌损伤的机制主要为加重氧化应激、干扰铁代谢，而免疫治疗主要是是通过激活全身免疫反应，抑制肿瘤细胞免疫逃逸［2-3］。

[收稿日期]2021-08-25　[修回日期]2022-03-08[基金项目]安徽省马鞍山市科技计划项目(YL⁃2019⁃02)[作者简介]宁　晔(1989-),男,硕士研究生,主治医师.[通信作者]唐丽宇,主任医师.E⁃mail:tly1965@[文章编号]1000⁃2200(2024)02⁃0187⁃05㊃临床医学㊃富血小板纤维蛋白联合Bio⁃Oss 骨粉修复颌骨囊肿术后骨缺损的疗效宁　晔,唐丽宇,龚飞飞,庄劭玉,夏华宽(安徽省马鞍山市人民医院口腔科,243000)[摘要]目的:观察使用富血小板纤维蛋白(platelet⁃rich fibrin,PRF)联合Bio⁃Oss 骨粉修复颌骨囊肿术后骨缺损的临床疗效㊂方法:选取颌骨囊肿术后存在一定大小范围的骨缺损病人共36例作为研究对象,随机分为2组,各18例㊂对照组病人单纯使用Bio⁃Oss 充填修复骨缺损;观察组病人使用PRF 联合Bio⁃Oss 充填颌骨囊肿造成的骨缺损空腔㊂所有病人术后分别于3㊁6㊁12个月进行定期随访观察,通过CBCT 影像学检查测量骨密度值评估临床疗效㊂结果:观察组颌骨囊肿术后伤口愈合良好,对照组有1例术后7d 创口出现轻度糜烂红肿,未见充填材料排异反应㊂影像学检查显示观察组较对照组病人颌骨缺损空腔内的充填材料随着时间推移与新生骨及周围骨组织生长良好,能够达到临床满意的骨组织修复效果㊂观察组术后3㊁6㊁12个月骨缺损区骨密度均高于对照组,差异均有统计学意义(P <0.05~P <0.01)㊂结论:PRF 联合Bio⁃Oss 骨粉可有效提高颌骨囊肿术后骨缺损的成骨疗效㊂[关键词]颌骨囊肿;富血小板纤维蛋白;Bio⁃Oss 骨粉;骨缺损[中图法分类号]R 782 [文献标志码]A DOI :10.13898/ki.issn.1000⁃2200.2024.02.010Effects of platelet⁃rich fibrin combinedwith Bio⁃Oss bone substitute in the repair of postoperative bone defect of jaw cystNING Ye,TANG Liyu,GONG Feifei,ZHUANG Shaoyu,XIA Huakuan(Department of Stomatology ,The People′s Hospital of Maanshan ,Maanshan Anhui 243000,China )[Abstract ]Objective :To observe the clinical efficacy of platelet⁃rich fibrin(PRF)combined with Bio⁃Oss bone substitute in the repair of postoperative bone defect of jaw cyst.Methods :A total of 36patients with bone defects in a certain range after maxillary cyst surgery were randomly divided into the control group and observation group(18cases in each group).The control group was treated with Bio⁃Oss filling to repair bone defects,and the observation group was treated with PRF combined with Bio⁃Oss filling to repair the cavity of bone defect caused by jaw cyst.All patients were regularly followed up for 3,6and 12months after surgery,and the CBCT imaging was used to measure bone mineral density to evaluate the clinical efficacy.Results :The wounds of jawbone cyst in the observation group healed well after surgery,1case with mild erosion and redness in the control group was identified after 7days of surgery,and no rejection reaction of filling material was be observed.The results of imaging examination showed that compared with the control group,the filling materials in the cavity of jaw defect in the observation group grew well with the new bone and surrounding bone tissue over time,and the bone tissue repair effect could achieve clinical satisfactory.The bone mineral density in observation group was higher than that in control group at 3,6and 12months after surgery(P <0.05to P <0.01).Conclusions :The PRF combined with Bio⁃Oss bonesubstitute can effectively promote the osteogenic effect of bone defect after maxillary cyst surgery.[Key words ]jaw cyst;platelet⁃rich fibrin;Bio⁃Oss bone substitute;bone defect 颌骨囊肿是临床上比较常见的造成颌骨缺损的疾病,手术摘除颌骨囊肿后所遗留的骨性空腔往往使得创口延期愈合或出现继发性感染[1]㊂颌骨缺损修复多采用囊腔植骨术和生物材料置入术,但是植骨术的骨来源大多为自体骨,需要开辟第二术区,给病人造成额外痛苦,生物材料置入也会存在一定的排异反应和感染风险[2]㊂近年来,我科使用富血小板纤维蛋白(platelet⁃rich fibrin,PRF)联合Bio⁃Oss 骨粉修复颌骨囊肿术后骨缺损取得了良好的临床疗效,现作报道㊂1　资料与方法1.1　病例选取　选取2019年11月至2020年8月于马鞍山市人民医院口腔科收住的颌骨囊肿术后存在一定范围的骨缺损病人共36例,随机分为2组,每组18例㊂其中观察组男11例,女7例,平均年龄35.24岁;对照组男13例,女5例,平均年龄37.13岁㊂所有病人的治疗过程符合‘赫尔辛基宣言“的要求,并得到了马鞍山市人民医院伦理委员会的批准㊂术前均告知病人对所接受的治疗㊁预后及可能出现的并发症情况,病人知情同意并签字为据㊂纳入标准:(1)年龄≥18周岁,无不良烟酒嗜好,口腔卫生较好,依从性强;(2)颌骨囊肿大小3.0cm×2.0cm×1.0cm ~5.0cm×4.0cm×3.0cm,囊肿摘除后呈箱状骨缺损㊂排除标准:(1)患有糖尿病㊁骨质疏松等影响骨愈合的全身系统性疾病;(2)颌骨囊肿摘除后呈节段性缺损严重,必须进行自体骨移植,钛板坚强内固定;(3)因自身血液质量不佳,无法制备出足量的PRF㊂1.2　材料及器械　Bio⁃Oss骨粉(Geistlich Biomaterials,瑞士);海奥生物胶原修复膜(烟台正海生物技术有限公司,中国);Trausim血液离心机及特定配套的采血管㊁搅拌器及压膜成形器等(江苏创英医疗器械有限公司,中国)㊂1.3　手术过程　1.3.1　术前准备　拍摄CBCT测量评估颌骨囊肿大小范围,满足纳入标准的病人予以手术知情告知㊂术前30min静脉滴注 头孢呋辛钠”1.5g,行预防性抗感染治疗㊂1.3.2　PRF的制备　根据术前囊肿大小范围,评估使用不抗凝真空负压采血管的数目并采集病人适量肘部静脉血后迅速放入Trausim血液离心机中,以3000r/min的速度离心14min㊂离心后可见采血管中血液由上至下分为3层:血清层㊁PRF层及红细胞层㊂打开采血管将血清层倒去,用镊子轻轻夹取黄色胶冻状的PRF置管外,将PRF放入压膜成形器中压制成PRF膜备用(见图1)㊂1.3.3　手术方法　常规消毒铺巾,局麻下术区采用角形或梯形切口,切开㊁翻瓣㊁去骨,充分暴露囊腔并完整摘除囊肿后,酌情拔除囊肿涉及无法保留的病灶牙㊂仔细搔刮根尖周围及囊腔骨壁,修整骨创缘后用2%碘酊烧灼骨腔,0.9%氯化钠溶液彻底冲洗㊂观察组病人将一部分PRF膜剪碎成颗粒状与Bio⁃Oss骨粉混合搅拌均匀后填入囊肿术后骨缺损空腔内,取PRF膜及海奥生物胶原膜各一份,双层覆盖于骨缺损创面;对照组单纯填入Bio⁃Oss骨粉,覆盖生物胶原膜㊂2组病人均对位严密缝合组织瓣,关闭创口㊂1.4　观察评估　所有病人术后分别于3㊁6㊁12个月进行定期随访观察㊂临床大体观察术区软组织愈合情况,拍摄CBCT影像学观察骨缺损修复情况,通过测量骨缺损区骨密度值,判断2组病人的骨修复情况(见图2~3)㊂1.5　统计学方法　采用独立样本t检验㊂2　结果 术后2组病人随访观察3~12个月㊂其中观察组病人术后7d创口均达到Ⅰ期愈合,CBCT影像学观察病人骨缺损空腔内的充填材料随着时间推移与新生骨及周围骨组织生长良好,可见植骨区与周围正常骨组织的界限和密度逐渐接近,颌骨囊肿术后骨缺损大小范围较术前明显缩小㊂对照组存在1例病人术后7d创口轻度糜烂红肿,但未见充填材料排异溢露,经积极抗感染治疗5d后好转,CBCT影像学观察相比较,术前2组病人骨缺损区骨密度值均较低,差异无统计学意义(P>0.05);观察组术后3㊁6㊁12个月骨缺损区骨密度均高于对照组,差异均有统计学意义(P<0.05~P<0.01)(见表1)㊂表1　2组病人骨缺损区骨密度平均值比较(x±s;Hu)分组术前术后3个月术后6个月术后12个月观察组115.74±22.74503.46±40.13587.82±31.83702.36±30.23对照组110.94±20.19405.24±29.72461.03±28.87547.36±35.87t0.678.3411.6314.02P>0.05<0.05<0.05<0.013　讨论 牙源性颌骨囊肿非常多见于青壮年颌骨的任何牙位㊂无论是好发于前牙区的根尖周囊肿,还是好发于后牙区的含牙囊肿或始基囊肿,手术摘除囊肿并拔除病灶牙后所遗留一定大小范围的骨缺损往往难以自行愈合,导致牙槽嵴宽度和高度得不到有效恢复,从而造成颌骨骨量不足影响后期义齿的修复[3]㊂目前,临床上多采用自体骨移植或人工骨充填的方法来修复颌骨囊肿术后造成一定大小范围的中㊁大型骨缺损[4]㊂尤其是近年来,随着种植义齿修复技术的成熟和推广,越来越多的颌骨囊肿术后病人需求种植义齿修复来提高自身的生活质量㊂为了促使病人能较快地修复颌骨缺损满足后期种植义齿修复,同时又能避免病人开辟第二术区的痛苦,本研究针对颌骨囊肿术后病人均采用国内外一致好评的Bio⁃Oss人工骨粉作为修复材料㊂大量研究已表明Bio⁃Oss骨粉晶体结构与人体骨的无机成分相似,材料颗粒具有多孔隙,溶解度高,表面性能大,无细胞毒性,生物相容性好的特性[5]㊂Bio⁃Oss修复骨缺损的机制在于骨粉颗粒多孔隙结构为成骨细胞提供附着支架,并在其表面沉积,随着骨形成中钙㊁磷离子缓慢释放,骨粉颗粒逐渐吸收,新骨逐渐钙化形成㊂虽然Bio⁃Oss在骨缺损处作为组织工程的支架优势明显,但是该材料只具备骨传导作用,缺乏较强的骨诱导和抗感染能力[6],故制备出一种成骨性能优良的Bio⁃Oss复合支架材料就显得尤为重要㊂研究[7]发现,在颌骨缺损修复中使用自体血小板浓缩物能够提高骨诱导能力,防止创口感染发生从而加快成骨效果形成㊂PRF制备工艺简单,血液提取后不需要额外添加凝血酶和抗凝剂就可以避免发生交叉感染和排异反应的风险[8-9]㊂另外PRF还富含大量生长因子㊁外周血干细胞及免疫细胞,在炎症调节和抗感染方面都发挥了较好的效果[10]㊂本研究将PRF和Bio⁃Oss制作成复合材料就是要发挥各自优势,促进范围较大骨缺损的成骨效果㊂本研究观察组病人术后3个月时已有新骨形成,术后6个月时骨缺损区新生骨面积明显扩大,到术后12个月新生骨组织密度进一步增强,与周围正常骨组织界限趋于模糊,有骨小梁生成㊂这也再次表明Bio⁃Oss所具有的三维多孔结构,有利于成骨细胞蔓延生长和毛细血管彼此连通,可以促进成骨细胞黏附和功能代谢[11]㊂同时,PRF中富含的血小板被激活后释放出转移性生长因子㊁表皮生长因子和血管内皮细胞生长因子等多种生长因子,一方面对成骨细胞的分化和增殖起着促进作用,另一方面抑制破骨细胞生成功能㊂这些生长因子之间具有协同效应并与骨形成蛋白相互作用,共同维持着组织环境的平衡,对骨缺损的成骨再生也起着十分重要的作用[12]㊂我们在临床观察发现,观察组病人的骨密度值明显比对照组高,经统计学数据分析也证实了观察组使用PRF联合Bio⁃Oss具有良好的促进骨修复效果㊂可见,随着Bio⁃Oss表面成骨细胞的聚集和PRF中大量生长因子浓度的提高,促进了成骨细胞增殖㊁矿化,从而形成有效的骨整合㊂本研究在Bio⁃Oss中加入PRF后,使得Bio⁃Oss材料既具有骨传导性,又具有骨诱导潜能,能够明显提高成骨效果㊂另外,在颌骨缺损空腔内仅仅充填复合人工骨材料是难以达到满意的成骨效果,良好的屏障膜覆盖,无张力严密缝合也至关重要㊂本研究中使用的口腔修复膜为一种牛皮处理制备的异种脱细胞真皮基质,可诱导成骨细胞贴附,参与生物降解过程,可阻挡牙龈上皮细胞进入骨缺损空腔内,维持成骨细胞生长的三维空间结构,创造出良好的骨再生环境[13]㊂研究中还充分利用PRF膜中的纤维蛋白属于血管化天然诱导物,有利于营养成分及氧气输入至骨髓干细胞周围,促进分化为成骨细胞的特性[14]㊂本研究中骨缺损空腔类型多为箱状,四周均有骨壁且唯一的开放创面覆盖屏障膜,能够有效防止咀嚼运动时骨充填材料向四周外溢㊂我们将PRF 凝胶压制成膜,发现PRF膜具有良好的抗剪切性和拉伸强度㊂为促进骨再生,防止创面感染,所有病人均使用PRF膜覆盖于人工骨材料表面㊂BORIE 等[15]研究就发现在骨增量术中使用PRF膜能够促进口腔软硬组织愈合,减少术后肿痛和感染㊂本研究对照组病人中有1例出现术区创面轻度红肿糜烂,经病情回溯发现为病人术后进食硬物致创面部分缝线疏松滑脱,再加上口腔卫生保持不佳所致,若创面覆盖PRF膜一定程度上就会减少创面感染的概率㊂综上所述,PRF联合Bio⁃Oss对颌骨囊肿术后骨缺损的修复具有一定的成骨效果,值得在临床上推广及应用㊂但在临床观察中,我们对如何选取合适的PRF与Bio⁃Oss的混合比例尚无统一标准,不同年龄段病人的自体血液和颌骨质量也有所差别,这些因素都会影响颌骨缺损修复的作用和疗效㊂因此PRF联合Bio⁃Oss修复颌骨囊肿术后骨缺损的稳定性还有待于长时间㊁大样本观察研究㊂[参考文献][1]　ZHANG ZY.Oral and maxillofacial surgery[M].7th ed.Beijing:People′s Medical Publishing House,2012:177.[2]　ZHOU J,DU RH.Assessment on the treatments for cyst of thejaws[J].J Oral Maxillofac Surg,2012,22(4):229. [3]　CHIAPASCO M,ROSSI A,MOTTA JJ,et al.Spontaneous boneregeneration after enucleation of large mandibular cysts:aradiographic computed analysis of27consecutive cases[J].JOral Maxillofac Surg,2000,58(9):942.[4]　AKRAM M,FAROOQ FM,SHAHZAD ML,et al.A comparison oftreating unicameral bone cyst using steroids and percutaneousautologous bone marrow aspiration injection[J].J Pak MedAssoc,2015,65(11Suppl3):S156.[5]　王国世,李韶伟,蔡露.牙种植采用引导骨再生术Bio⁃oss吸收的定量分析[J].上海口腔医学,2012,21(3):317. [6]　SIVOLELLA S,BRESSAN E,SALATA LA,et al.Deproteinizedbovine bone mineral particles and osseointegration of implantswithout primary bone contact:an experimental study in dogs[J].Clin Oral Implants Res,2014,25(3):296.[7]　AMIT A.Evolution current status and advances in application ofplatelet concentrate in periodontics and implantology?[J].World J Clin Cases,2017(5):159.[8]　DOHAN DM,CHOUKROUN J,DISS A,et al.Platelet⁃rich fibrin(PRF):a second⁃generation platelet concentrate.PartⅢ:leucocyte activation:a new feature for platelet concentrates[J].Oral Surg Oral Med Oral Pathol Oral Radiol Endod,2006,101(3):e51.[9]　方冬冬,后军,杨全全,等.富血小板纤维蛋白复合骨诱导在颌骨缺损中的应用疗效[J].安徽医学,2016,37(7):868. [10]　周延民,付丽.富血小板纤维蛋白在口腔软硬组织再生中的作用 回顾与展望[J].口腔医学,2018,38(11):961. [11]　SHAH R,THOMAS R,MEHTA DS.An update on the protocolsand biologic actions of platelet rich fibrin in dentistry[J].Eur JProsthodont Restor Dent,2017,25(2):64.[12]　AZITA T,HOSSEIN B,FEREYDOUN P,et al.The effect ofautologous leukocyte platelet rich fibrin on the rate of orthodontictooth movement:a prospective randomized clinical trial[J].WorldJ Clin Cases,2017(5):159.[13]　DEYHIMI P,RAZAVI SM,SHAHNASERI S,et al.Rare andextensive malignant melanoma of the oral cavity:report of twocases[J].J Dent(Shiraz),2017,18(3):227.。